LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

Myomo to Participate in Two Investor Conferences in September

September 05, 2024 | Last Trade: US$6.43 0.00 0.00

BOSTON / Sep 05, 2024 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be participating in two investor conferences during the month of September.

  • Paul Gudonis, chairman and chief executive officer, and David Henry, chief financial officer, will present and host one-on-one meetings at the HC Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel. Management’s presentation will be available for viewing beginning at 7:00 a.m. ET on September 9th, and one-on-one meetings with investors will be held virtually on September 9th and 11th. Visit www.hcwevents.com/annualconference to register for the conference to view the presentation or request a meeting,
  • David Henry will host one-on-one meetings at the Lake Street 8th Annual Best Ideas Growth “Big 8” Conference at the Yale Club in New York on September 12, 2024. This conference consists of one-on-one meetings between Company management and investors. Visit https://www.lakestreetcapitalmarkets.com or contact your Lake Street representative to participate in the conference.

About Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.

Viking Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB